Ensysce Biosciences reports Q2 2025 net loss of $1.7M, advances Phase 3 trial for PF614

Ensysce Biosciences, Inc.

2025-Q2 EPS reported -$2.04 revenue$2,691,210

Cash and equivalents $2.2M at June 30, 2025, down from $3.5M at Dec 31, 2024.
Net loss $1.7M in Q2 2025 vs $2.0M loss in Q2 2024; R&D expenses rose to $1.9M from $0.9M.
Federal grant revenue $1.4M in Q2 2025 vs $0.2M in Q2 2024, driven by MPAR study activity.
Initiated pivotal Phase 3 trial (PF614-301) for post-surgical pain; Rho, Inc. engaged as CRO.
Received $5.3M NIDA installment and U.S. patent allowance for OUD candidate PF9001.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.